Document is current
Any future updates will be listed below
-
Authors
Vinyard, Michael E. https://orcid.org/0000-0001-8167-1807
Rasmussen, Anders W.
Li, Ruitong
Klein, Allon M.
Getz, Gad https://orcid.org/0000-0002-0936-0753
Pinello, Luca https://orcid.org/0000-0003-1109-3823
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1F31CA257625)
Paul C. Zamecnik Chair in Oncology at the Mass General Cancer Center
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 30 October 2025
First Online: 18 December 2025
Competing interests
: G.G. receives research funds from IBM, Pharmacyclics/Abbvie, Bayer, Genentech, Calico, Ultima Genomics, Inocras, Google, Kite and Novartis and is an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye, MinimuMM-seq and DLBclass. He is a founder and consultant and holds privately held equity in Scorpion Therapeutics; he is also a founder of, and holds privately held equity in, Predicta Biosciences; and holds privately held equity in Antares Therapeutics. M.E.V. is a founder of, and holds privately held equity in, Quintessence Laboratories, Inc. The other authors declare no competing interests.
